×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PTCT – ptc therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PTCT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/12
08:51 am
ptct
PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference [Yahoo! Finance]
Low
Report
PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference [Yahoo! Finance]
1/12
08:30 am
ptct
PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
Low
Report
PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
1/8
04:30 pm
ptct
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/8
08:02 am
ptct
PTC Therapeutics (NASDAQ:PTCT) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
PTC Therapeutics (NASDAQ:PTCT) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
1/3
01:08 am
ptct
PTC Therapeutics (NASDAQ:PTCT) was upgraded by analysts at Wall Street Z
Low
Report
PTC Therapeutics (NASDAQ:PTCT) was upgraded by analysts at Wall Street Z
12/30
04:14 pm
ptct
PTC Therapeutics (NASDAQ:PTCT) had its "hold (c)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
PTC Therapeutics (NASDAQ:PTCT) had its "hold (c)" rating reaffirmed by analysts at Weiss Ratings.
12/23
02:16 am
ptct
Japan Sephience Approval Could Be A Game Changer For PTC Therapeutics' (PTCT) Rare-Disease Strategy [Yahoo! Finance]
Low
Report
Japan Sephience Approval Could Be A Game Changer For PTC Therapeutics' (PTCT) Rare-Disease Strategy [Yahoo! Finance]
12/23
01:35 am
ptct
PTC Therapeutics (PTCT): Valuation Check After First Japan Approval Completes Global Sephience Launch [Yahoo! Finance]
Low
Report
PTC Therapeutics (PTCT): Valuation Check After First Japan Approval Completes Global Sephience Launch [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/12
05:20 pm
ptct
Form 4 PTC THERAPEUTICS, INC. For: Jan 08 Filed by: Utter Christine Marie
Low
Report
Form 4 PTC THERAPEUTICS, INC. For: Jan 08 Filed by: Utter Christine Marie
1/12
05:20 pm
ptct
Form 4 PTC THERAPEUTICS, INC. For: Jan 08 Filed by: Pauwels Eric
Low
Report
Form 4 PTC THERAPEUTICS, INC. For: Jan 08 Filed by: Pauwels Eric
1/12
05:20 pm
ptct
Form 4 PTC THERAPEUTICS, INC. For: Jan 08 Filed by: Golden Lee Scott
Low
Report
Form 4 PTC THERAPEUTICS, INC. For: Jan 08 Filed by: Golden Lee Scott
1/12
05:20 pm
ptct
Form 4 PTC THERAPEUTICS, INC. For: Jan 08 Filed by: Boulding Mark Elliott
Low
Report
Form 4 PTC THERAPEUTICS, INC. For: Jan 08 Filed by: Boulding Mark Elliott
1/12
05:20 pm
ptct
Form 4 PTC THERAPEUTICS, INC. For: Jan 08 Filed by: Klein Matthew B.
Low
Report
Form 4 PTC THERAPEUTICS, INC. For: Jan 08 Filed by: Klein Matthew B.
1/12
05:20 pm
ptct
Form 4 PTC THERAPEUTICS, INC. For: Jan 08 Filed by: Almstead Neil Gregory
Low
Report
Form 4 PTC THERAPEUTICS, INC. For: Jan 08 Filed by: Almstead Neil Gregory
1/12
12:00 pm
ptct
Form 8-K PTC THERAPEUTICS, INC. For: Jan 12
Low
Report
Form 8-K PTC THERAPEUTICS, INC. For: Jan 12
1/9
04:11 pm
ptct
Form 144 PTC THERAPEUTICS, INC. Filed by: Boulding Mark Elliott
Low
Report
Form 144 PTC THERAPEUTICS, INC. Filed by: Boulding Mark Elliott
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/6
Biogen Stock Rockets On Key Patent Win — Is It Time To Buy Shares? [Investor's Business Daily]
10.5%
3/4 PTC Therapeutics, Inc. (NASDAQ: PTCT) had its "hold" rating re-affirmed by analysts at Barclays PLC. They now have a $51.00 price target on the stock. 9.3%
10/29 PTC Therapeutics' (PTCT) CEO Stuart Peltz on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 7.9%
5/8 PTC Therapeutics to Participate at Upcoming Investor Conferences 7.9%
3/18 Form 4 PTC THERAPEUTICS, INC. For: Mar 16 Filed by: SCHMERTZLER MICHAEL 6.2%
6/17 PTC Therapeutics, Inc. (NASDAQ: PTCT) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. 5.9%
3/18 Form SEC STAFF LETTER PTC THERAPEUTICS, INC. 5.7%
10/2 Risdiplam Spinal Muscular Atrophy Data Demonstrating Continued Benefit Presented at World Muscle Society Congress 5.6%
3/30 PTC Therapeutics, Inc. (NASDAQ: PTCT) was downgraded by analysts at TheStreet from a "c-" rating to a "d" rating. 5.5%
4/17 PTC Therapeutics Announces New Leadership Appointments 4.8%
3/4 PTC Therapeutics, Inc. (NASDAQ: PTCT) had its "hold" rating re-affirmed by analysts at Barclays PLC. They now have a $51.00 price target on the stock. 9.3%
10/29 PTC Therapeutics' (PTCT) CEO Stuart Peltz on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 7.9%
5/8 PTC Therapeutics to Participate at Upcoming Investor Conferences 7.9%
3/18 Form 4 PTC THERAPEUTICS, INC. For: Mar 16 Filed by: SCHMERTZLER MICHAEL 6.2%
6/17 PTC Therapeutics, Inc. (NASDAQ: PTCT) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. 5.9%
3/18 Form SEC STAFF LETTER PTC THERAPEUTICS, INC. 5.7%
10/2 Risdiplam Spinal Muscular Atrophy Data Demonstrating Continued Benefit Presented at World Muscle Society Congress 5.6%
3/30 PTC Therapeutics, Inc. (NASDAQ: PTCT) was downgraded by analysts at TheStreet from a "c-" rating to a "d" rating. 5.5%
4/17 PTC Therapeutics Announces New Leadership Appointments 4.8%
TOP News Decliners
3/16
PTC Therapeutics Announces Management Change
-19.5%
3/11 PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -11.4%
9/17 PTC Therapeutics Announces Proposed Public Offering of Common Stock -11.3%
4/29 PTC Therapeutics Q1 2020 Earnings Preview [Seeking Alpha] -9.4%
3/2 Form 8-K PTC THERAPEUTICS, INC. For: Mar 02 -5.8%
4/30 Q1/2020 3/31/2020 EPS -1.810 ZacksConsensus -1.080 ActVsEst (0.730) - Miss -5.7%
9/30 PTC Therapeutics, Inc. (NASDAQ: PTCT) was given a new $62.00 price target on by analysts at Citigroup Inc. They now have a "buy" rating on the stock. -4.7%
8/5 PTC Therapeutics Expands Presence in New Jersey by Securing State-of-the-Art Biologics Facility -4.6%
1/13 PTC Therapeutics Provides Corporate Update and Highlights Pipeline Progress at 2020 J.P. Morgan Healthcare Conference -4.2%
6/13 Form 8-K PTC THERAPEUTICS, INC. For: Jun 12 -4.1%
3/11 PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -11.4%
9/17 PTC Therapeutics Announces Proposed Public Offering of Common Stock -11.3%
4/29 PTC Therapeutics Q1 2020 Earnings Preview [Seeking Alpha] -9.4%
3/2 Form 8-K PTC THERAPEUTICS, INC. For: Mar 02 -5.8%
4/30 Q1/2020 3/31/2020 EPS -1.810 ZacksConsensus -1.080 ActVsEst (0.730) - Miss -5.7%
9/30 PTC Therapeutics, Inc. (NASDAQ: PTCT) was given a new $62.00 price target on by analysts at Citigroup Inc. They now have a "buy" rating on the stock. -4.7%
8/5 PTC Therapeutics Expands Presence in New Jersey by Securing State-of-the-Art Biologics Facility -4.6%
1/13 PTC Therapeutics Provides Corporate Update and Highlights Pipeline Progress at 2020 J.P. Morgan Healthcare Conference -4.2%
6/13 Form 8-K PTC THERAPEUTICS, INC. For: Jun 12 -4.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: